Shopping Cart
Remove All
Your shopping cart is currently empty
XmAb5485 is a humanized anti-CD40 monoclonal antibody engineered with an Fc domain modification, exhibiting high affinity for Fc-γ receptors. It effectively induces antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. Additionally, XmAb5485 suppresses tumor cell proliferation and triggers apoptosis. This compound demonstrates pronounced cytotoxicity against lymphoma, leukemia, multiple myeloma cell lines, and primary cancer cells.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | XmAb5485 is a humanized anti-CD40 monoclonal antibody engineered with an Fc domain modification, exhibiting high affinity for Fc-γ receptors. It effectively induces antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. Additionally, XmAb5485 suppresses tumor cell proliferation and triggers apoptosis. This compound demonstrates pronounced cytotoxicity against lymphoma, leukemia, multiple myeloma cell lines, and primary cancer cells. |
| In vitro | XmAb5485 exhibits significant antibody-dependent cellular phagocytosis (ADCP) in Ramos cells. Additionally, it suppresses the proliferation and induces apoptosis of various primary patient-derived CLL, MCL cells, and plasma cell leukemia cells through antibody-dependent cell-mediated cytotoxicity (ADCC). |
| In vivo | XmAb5485 (6 mg/kg) successfully cured 80% of mice with detectable tumors and demonstrated significant antitumor activity in a mouse model with established large-volume (210-350 mm³) subcutaneous Ramos xenograft tumors. |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.